If you are looking into stocks that might have made attractive gains so far this morning, then it might be a good move to look into the Polarity TE Inc (NASDAQ:PTE) stock, which has soared by 25%.
This morning the company announced that its diabetic foot ulcer product SkinTE managed to meet both the primary and secondary endpoints in a multi-center randomized controlled study. The company announced that as many as 70% of the 50 patients, who were treated with SkinTE and the standard of care, had their wounds cured in 12 weeks.
That was the primary endpoint of the study. On the other hand, the percent area reduction for those who underwent the above treatment was as high as 84%. In comparison, patients who only received standard of care experienced a reduction of only 54%. This was the secondary endpoint. Now it remains to be seen if the Polarity stock can continue to add to its gains through the rest of the day.
At the time of writing, PTE stock is up by 23.18% at $1.20 after hitting a session high of $1.38.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.